Sander Slootweg MSc
Managing Partner
Azafaros aims to be a beacon of hope for patients living with severe rare genetic diseases and their families.
Founded in 2018 with a deep understanding of rare genetic disease mechanisms and led by a team of highly experienced industry experts, Azafaros aims to build a pipeline of disease-modifying therapeutics to offer patients and their families new treatment options.
The company's lead clinical-staged program is AZ-3102, a highly differentiated, orally available, small molecule with the potential to treat GM1 and GM2 Gangliosidosis and other metabolic disorders. By applying their know-how, network, and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them.
Industry
Biotech
Status
Current
Location
The Netherlands
At Azafaros, we are driven by the urgency to bring transformative therapies to children and families affected by rare metabolic diseases with neurological involvement. Forbion’s deep knowledge of drug development, including in rare diseases, combined with their strategic guidance and long-term commitment, has been instrumental in advancing our pipeline and strengthening our ability to deliver meaningful impact for patients worldwide.Dr. Stefano Portolano
CEO of Azafaros
€200m
raised to date
Forbion team
Carlo Incerti MD
Operating Partner
Nanna Lüneborg PhD, MBA
General Partner
Audrey Cacaly MSc
Principal